SCHEMBL7409529

SCHEMBL7409529

COc1ccc2ccc(C(=O)c3cc(OC)c(OC)cc3OC(C)=O)cc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.57
HTT P42858 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
NPC1 O15118 1/20 0.52
ALDH1A1 P00352 3/20 0.52
POLB P06746 1/20 0.51
GAA P10253 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
KDM4E B2RXH2 1/20 0.49
CYP2C9 P11712 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
TSHR P16473 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
MAPK1 P28482 1/20 0.46
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7411615 0.90 MAPT (0.51) MAPTHTTNPSR1NPC1ALDH1A1
SCHEMBL18288072 0.79 KDM4E (0.66) MAPTHTTNPSR1NPC1ALDH1A1
SCHEMBL6615739 0.78 KMT2A (0.54) MAPTHTTNPSR1NPC1ALDH1A1
SCHEMBL6617275 0.78 TSHR (0.53) MAPTHTTNPSR1NPC1ALDH1A1
SCHEMBL7410935 0.78 POLB (0.62) MAPTHTTNPSR1NPC1ALDH1A1
SCHEMBL6611954 0.78 MAPT (0.63) MAPTHTTNPSR1ALDH1A1SMN1; SMN2
SCHEMBL5554438 0.77 NPC1 (0.63) MAPTHTTNPSR1NPC1ALDH1A1
SCHEMBL7407945 0.76 TSHR (0.50) MAPTHTTNPSR1ALDH1A1SMN1; SMN2
SCHEMBL7411516 0.76 TSHR (0.54) MAPTHTTNPSR1ALDH1A1POLB
SCHEMBL7409955 0.76 TSHR (0.42) MAPTHTTNPSR1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002088096-A1 COMPOUNDS INHIBITING CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, PREPARATION AND USES THEREOF NEURO3D (FR) 2002-11-07 WO disclosed